A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Przewidywany czas życia co najmniej 12 tygodni.
- •Potwierdzony chłoniak z komórek płaszcza (MCL) z określonymi cechami w ciągu ostatnich 12 miesięcy.
- •Choroba nawróciła lub nie zareagowała na poprzednie leczenie.
- •Pacjent otrzymał co najmniej jedną linię leczenia systemowego, w tym lek z grupy inhibitorów BTK, oraz inną terapię systemową.
- •Istnieje możliwość pobrania próbki tkanki guza do badań.
- •Widoczna na badaniu tomografii komputerowej zmiana (węzeł chłonny lub inna tkanka) o odpowiednich rozmiarach.
- •Ogólny stan zdrowia pacjenta pozwala na udział w badaniu (skala ECOG 0, 1 lub 2).
✗ Disqualifies
- •Ciąża, karmienie piersią lub zamiar zajścia w ciążę w trakcie badania lub po jego zakończeniu.
- •Chłoniak z komórek płaszcza w postaci białaczkowej (bez obecności węzłów chłonnych).
- •Wcześniejsze ciężkie reakcje alergiczne na leki podobne do tych stosowanych w badaniu.
- •Przeciwwskazania do stosowania niektórych leków badanych w tym protokole.
- •Wcześniejsze leczenie lekiem glofitamab lub podobnymi lekami.
- •Wcześniejsze leczenie terapią komórkami CAR-T.
- •Przyjmowanie innych leków na raka lub inhibitorów BTK w ciągu ostatnich 2 tygodni przed rozpoczęciem leczenia w badaniu.
- •Chłoniak obejmujący ośrodkowy układ nerwowy (mózg, rdzeń kręgowy).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (77)
Alta Bates Summit Medical Center
Berkeley, United States
City of Hope Cancer Center
Duarte, United States
University of California Los Angeles (UCLA) - Cancer Care - Santa Monica
Santa Monica, United States
Yale Cancer Center
New Haven, United States
Georgetown University
Washington D.C., United States
University of Miami
Coral Gables, United States
Indiana University
Indianapolis, United States
University of Michigan Health System
Ann Arbor, United States
St. Luke's Hospital
Chesterfield, United States
Renown Regional Medical Center
Reno, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Hematology Oncology Associates of Central New York
East Syracuse, United States
University of Rochester
Rochester, United States
Medical University of S. Carolina
Charleston, United States
Avera Cancer Institute
Sioux Falls, United States
Renovatio Clinical - El Paso
El Paso, United States
Renovatio Clinical
The Woodlands, United States
University of Virginia
Charlottesville, United States
West Virginia University
Morgantown, United States
Calvary Mater Newcastle
Waratah, Australia
Royal Adelaide Hospital
Adelaide, Australia
Epworth Hospital
Richmond, Australia
Hospital Sao Rafael - HSR
Salvador, Brazil
ICTR Curitiba
Curitiba, Brazil
Hospital Mae de Deus
Porto Alegre, Brazil
Hospital Paulistano
São Paulo, Brazil
Hospital Alemao Oswaldo Cruz
São Paulo, Brazil
Hospital A. C. Camargo
São Paulo, Brazil
Instituto D'Or Pesquisa e Ensino
São Paulo, Brazil
Americas Medical City
Rio de Janeiro, Brazil
Beneficencia Portuguesa de Sao Paulo
São Paulo, Brazil
Victoria Hospital - London Health Sciences Centre
London, Canada
The Ottawa Hospital - General Campus
Ottawa, Canada
Princess Margaret Cancer Center
Toronto, Canada
Beijing Tong Ren Hospital, Capital Medical University
Beijing, China
The First Hospital of Jilin University
Changchun, China
West China Hospital of Sichuan University
Chengdu, China
Chongqing Cancer Hospital
Chongqing, China
Fujian Provincial Cancer Hospital
Fuzhou, China
Sun yat-sen University Cancer Center
Guangzhou, China
Guangxi Cancer Hospital of Guangxi Medical University
Nanning, China
Fudan University Shanghai Cancer Center
Shanghai, China
The First Affiliated Hospital of China Medical University
Shenyang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Henan Cancer Hospital
Zhengzhou, China
Hopital Claude Huriez
Lille, France
Hopital Saint Eloi
Montpellier, France
CHU NANTES - Hôtel Dieu
Nantes, France
INSTITUT CURIE_SITE PARIS - Service d'Oncologie Médicale.
Paris, France
Hopital Necker
Paris, France
Policlinico S.Orsola-Malpighi
Bologna, Italy
Humanitas Gavazzeni
Bergamo, Italy
Irccs Istituto Europeo Di Oncologia (IEO)
Milan, Italy
SC Ematologia, AO SS. Antonio e Biagio e C. Arrigo
Alessandria, Italy
A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette
Turin, Italy
Auxilio Mutuo Cancer Center
San Juan, Puerto Rico
Chungnam National University Hospital
Daejeon, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitario Puerta del Mar
Cadiz, Spain
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital General Universitario J.M Morales Meseguer
Murcia, Spain
Skånes University Hospital, Skånes Department of Onclology
Lund, Sweden
Akademiska sjukhuset, Onkologkliniken
Uppsala, Sweden
National Taiwan Universtiy Hospital
Taipei, Taiwan
Chang Gung Medical Foundation - Linkou
Taoyuan, Taiwan
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom
Lincolnshire County Hospital
Lincoln, United Kingdom
University College London Hospital
London, United Kingdom
Christie Hospital Nhs Trust
Manchester, United Kingdom
Oxford Churchill Hospital
Oxford, United Kingdom
Derriford Hospital
Plymouth, United Kingdom
Trial contact
Reference Study ID Number: GO43878 https://forpatients.roche.com/ No attachments to email below.
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.